
De-risking neurology drug development with better mouse models
Episode 203
Today we welcome Brandy Wilkinson, CEO of GemPharmatech, and Rikki Feng, the company’s Neuroscience Pipeline Leader. Our discussion focuses on a persistent challenge in drug development: neurology’s stubbornly high clinical failure rates. GemPharmatech is tackling this head-on with proprietary models for Alzheimer’s, Parkinson’s, and blood-brain barrier transport that better mirror human disease biology. We explore why mouse models matter more in neurology than in other fields, the design principles behind these next-generation tools, and how smarter preclinical partnerships can help therapeutic developers de-risk programs earlier. 00:00 Welcome Brandy Wilkinson and Rikki Feng 03:17 GemPharmatech's mission 06:26 Why mouse models matter in neurology 11:11 Common translation gaps in neurology 18:09 Designing proprietary neurological disease models 25:45 Building stronger CRO strategic partnerships 33:58 An optimistic future of neuroscience research This episode was produced with the support of GemPharmatech. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter To dive deeper into the topic: Neurological diseases R&D trends and breakthrough innovations Brain Awareness Week: could ongoing R&D spur neuroscience breakthroughs? 11 neuroscience biotech companies you should know about
Publisher
Beyond Biotech - the podcast from Labiotech
Published
June 26, 2026
Duration
41 min
Format
Podcast
Category
Issues · Tech News
Source
RSS feed
Host
Labiotech
Beyond Biotech - the podcast from Labiotech
@beyondbiotechthepodcastfroml
#riskingneurologydrug #bettermousemodels
